IP Library Granted Patent US 11,091,534
Granted Patent B2
US 11,091,534 · App. 16/154,310 · Granted Aug 17, 2021

Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

Inventors: Ekta Seth Chhabra (Framingham, MA); Tongyao Liu (Lexington, MA); Pei-yun Chang (Menlo Park, CA); Robert T. Peters (Needham, MA); John Kulman (Belmont, MA); Haiyan Jiang (Belmont, MA)
Assignee: Bioverativ Therapeutics Inc.
C07K14/755A61K38/36A61K38/37A61K47/55C07K16/00C12N15/11C07K2319/00C07K2319/30C07K2319/31C07K2319/35C07K2319/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,534
App. No.
16/154,310
Granted
Aug 17, 2021
Kind
B2
Abstract

The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

Claims (32)

1. A set of polynucleotides encoding a chimeric protein, wherein the set of polynucleotides comprises (i) a first polynucleotide and (ii) a second polynucleotide,

wherein the (i) first polynucleotide encodes a first polypeptide chain comprising:

(a) a von Willebrand Factor (VWF) fragment comprising a D1 domain, a D2 domain, a D′ domain, and a D3 domain of VWF, wherein the VWF fragment encoded by the first polynucleotide comprises an amino acid sequence having at least 95% sequence identity to amino acids 23 to 1240 of SEQ ID NO: 2;

(b) a first extended length polypeptide (XTEN) sequence, and

(c) a first Fc region;

wherein the (ii) second polynucleotide encodes a second polypeptide chain comprising:

(a) a Factor VIII (FVIII) protein comprising amino acids 1 to 745 of full-length mature human factor VIII (SEQ ID NO: 4) with a second XTEN sequence inserted within the FVIII protein immediately downstream of an insertion site corresponding to residue 745 of full-length mature human FVIII, and

(b) a second Fc region,

wherein the VWF fragment prevents binding of endogenous VWF to FVIII;

wherein the D′ domain of VWF encoded by the first polynucleotide comprises an amino acid sequence having at least 95% sequence identity to amino acids 764 to 866 of SEQ ID NO: 2;

wherein the VWF fragment does not form a dimer or multimer of VWF;

wherein the first XTEN sequence is linked to or associated with the first Fc region by a thrombin cleavable linker; and

wherein the first XTEN sequence and the second XTEN sequence comprise the amino acid sequence of SEQ ID NO: 131.

2. The set of polynucleotides of claim 1 , further comprising a polynucleotide encoding a Paired basic Amino acid Cleaving Enzyme (PACE).

3. A host cell comprising the set of polynucleotides of claim 1 .

4. The host cell of claim 3 , wherein the host cell is a mammalian cell.

5. The host cell of claim 4 , wherein the mammalian cell is a HEK293 cell, CHO cell, or BHK cell.

6. The host cell of claim 4 , wherein the mammalian cell is a HEK293 cell.

7. The host cell of claim 4 , wherein the mammalian cell is a HEK293F cell.

8. The host cell of claim 3 , wherein the set of polynucleotides are stably transfected in the host cell.

9. A stable cell line comprising the host cell of claim 8 .

10. A host cell comprising the set of polynucleotides according to claim 2 .

11. The host cell of claim 10 , wherein the host cell is a HEK293F cell.

12. The set of polynucleotides of claim 1 , wherein the FVIII protein encoded by the second polynucleotide is a single chain FVIII isoform.

13. The set of polynucleotides of claim 1 , wherein the D′ domain of VWF encoded by the first polynucleotide comprises the amino acid sequence according to amino acids 764 to 866 of SEQ ID NO: 2.

14. The set of polynucleotides of claim 1 , wherein the D3 domain of VWF encoded by the first polynucleotide comprises an amino acid sequence having at least 95% sequence identity to amino acids 867 to 1240 of SEQ ID NO: 2.

15. The set of polynucleotides of claim 1 , wherein the VWF fragment encoded by the first polynucleotide comprises an amino acid sequence having at least 99% sequence identity to amino acids 23 to 1240 of SEQ ID NO: 2, wherein the VWF fragment further comprises a signal peptide of VWF corresponding to amino acids 1 to 22 of SEQ ID NO: 2.

16. The set of polynucleotides of claim 1 , wherein the first polypeptide chain comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 119.

17. The set of polynucleotides of claim 1 , wherein the second polypeptide chain comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 103.

18. The set of polynucleotides of claim 1 , wherein the VWF fragment encoded by the first polynucleotide comprises amino acids 764 to 1240 of SEQ ID NO: 119.

19. The set of polynucleotides of claim 1 , wherein the VWF fragment encoded by the first polynucleotide consists of amino acids 764 to 1240 of SEQ ID NO: 119.

20. The set of polynucleotides of claim 16 , wherein the second polypeptide chain comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 103.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2021
From: JIANG, HAIYAN
To: BIOGEN MA INC.
Reel/Frame 057515/0973 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2021
From: BIOGEN MA INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 057517/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: CHHABRA, EKTA SETH; LIU, TONGYAO; PETERS, ROBERT T.; KULMAN, JOHN
To: BIOGEN MA INC.
Reel/Frame 056665/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: CHANG, PEI-YUN
To: AMMUNIX OPERATING INC.
Reel/Frame 056665/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: AMMUNIX OPERATING INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 056665/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: BIOGEN MA INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 056680/0921 →
Continuity (8)
Division 14413765
Provisional Application 61670401 · Jul 11, 2012
Provisional Application 61759819 · Feb 1, 2013
Provisional Application 61801504 · Mar 15, 2013
Provisional Application 61801544 · Mar 15, 2013
Provisional Application 61827158 · May 24, 2013
Provisional Application 61840811 · Jun 28, 2013
Related Publication 20190169267A1 · Jun 6, 2019
Cited By (2)
US 12,398,176 US 12,617,839